Format
Sort by

Send to

Choose Destination

Search results

Items: 1 to 20 of 29

1.

Emerging roles of sodium-glucose cotransporter 2 inhibitors in cardiology.

Tanaka A, Node K.

J Cardiol. 2016 Dec 30. pii: S0914-5087(16)30297-0. doi: 10.1016/j.jjcc.2016.10.019. [Epub ahead of print] Review.

PMID:
28043708
2.

Berardinelli-Seip Congenital Lipodystrophy.

Van Maldergem L.

In: Pagon RA, Adam MP, Ardinger HH, Wallace SE, Amemiya A, Bean LJH, Bird TD, Ledbetter N, Mefford HC, Smith RJH, Stephens K, editors. GeneReviews® [Internet]. Seattle (WA): University of Washington, Seattle; 1993-2017.
2003 Sep 8 [updated 2016 Dec 8].

3.

Genitourinary infections in diabetic patients in the new era of diabetes therapy with sodium-glucose cotransporter-2 inhibitors.

Rizzi M, Trevisan R.

Nutr Metab Cardiovasc Dis. 2016 Nov;26(11):963-970. doi: 10.1016/j.numecd.2016.07.006. Review.

PMID:
27514605
4.

Sodium-glucose cotransporter 2 inhibition: cardioprotection by treating diabetes-a translational viewpoint explaining its potential salutary effects.

de Leeuw AE, de Boer RA.

Eur Heart J Cardiovasc Pharmacother. 2016 Oct;2(4):244-55. doi: 10.1093/ehjcvp/pvw009. Review.

5.

SGLT2 Inhibitors: Glucotoxicity and Tumorigenesis Downstream the Renal Proximal Tubule?

Bertinat R, Nualart F, Yáñez AJ.

J Cell Physiol. 2016 Aug;231(8):1635-7. doi: 10.1002/jcp.25286. Review.

PMID:
26661279
6.

Sodium-Glucose Cotransporter Inhibitors: Effects on Renal and Intestinal Glucose Transport: From Bench to Bedside.

Mudaliar S, Polidori D, Zambrowicz B, Henry RR.

Diabetes Care. 2015 Dec;38(12):2344-53. doi: 10.2337/dc15-0642. Review.

PMID:
26604280
7.

The Novel Role of the Kidney in Diabetes Management: Sodium-Glucose Co-Transporter 2 Inhibitors.

Swislocki AL, Jialal I.

Metab Syndr Relat Disord. 2015 Sep;13(7):287-91. doi: 10.1089/met.2015.1504. Review.

PMID:
25893855
8.

Phenotype standardization for drug-induced kidney disease.

Mehta RL, Awdishu L, Davenport A, Murray PT, Macedo E, Cerda J, Chakaravarthi R, Holden AL, Goldstein SL.

Kidney Int. 2015 Aug;88(2):226-34. doi: 10.1038/ki.2015.115.

9.

Interactions of vitamin D and the proximal tubule.

Chesney RW.

Pediatr Nephrol. 2016 Jan;31(1):7-14. doi: 10.1007/s00467-015-3050-5. Review.

PMID:
25618772
10.

Beyond Glycosuria: Exploring the intrarenal effects of SGLT₋₂ inhibition in diabetes.

Thomas MC, Jandeleit-Dahm K, Bonnet F.

Diabetes Metab. 2014 Dec;40(6 Suppl 1):S17-22. doi: 10.1016/S1262-3636(14)72691-6. Review.

11.

Renal Fanconi syndrome: taking a proximal look at the nephron.

Klootwijk ED, Reichold M, Unwin RJ, Kleta R, Warth R, Bockenhauer D.

Nephrol Dial Transplant. 2015 Sep;30(9):1456-60. doi: 10.1093/ndt/gfu377. Review.

PMID:
25492894
12.

Sodium glucose co-transporter 2 inhibitors and their mechanism for improving glycemia in patients with type 2 diabetes.

Davidson JA, Kuritzky L.

Postgrad Med. 2014 Oct;126(6):33-48. doi: 10.3810/pgm.2014.10.2819. Review.

PMID:
25414933
13.

[Executive summary of the recommendations on the evaluation and management of renal disease in human immunodeficiency virus-infected patients].

Panel de Expertos del Grupo de Estudio de Sida (GESIDA).; la Sociedad Española de Enfermedades Infecciosas y Microbiología Clínica (SEIMC).; la Sociedad Española de Nefrología (SEN).; la Sociedad Española de Bioquímica Clínica y Patología Molecular (SEQC)., Gorriz JL, Gutiérrez F, Trullàs JC, Arazo P, Arribas JR, Barril G, Cervero M, Cofán F, Domingo P, Estrada V, Fulladosa X, Galindo MJ, Gràcia S, Iribarren JA, Knobel H, López-Aldeguer J, Lozano F, Martínez-Castelao A, Martínez E, Mazuecos MA, Miralles C, Montañés R, Negredo E, Palacios R, Pérez-Elías MJ, Portilla J, Praga M, Quereda C, Rivero A, Santamaría JM, Sanz J, Sanz J, Miró JM.

Enferm Infecc Microbiol Clin. 2014 Nov;32(9):583-97. doi: 10.1016/j.eimc.2014.09.002. Spanish.

PMID:
25303781
14.

Novel antiretroviral drugs and renal function monitoring of HIV patients.

Maggi P, Montinaro V, Mussini C, Di Biagio A, Bellagamba R, Bonfanti P, Calza L, Cherubini C, Corsi P, Gargiulo M, Montella F, Rusconi S.

AIDS Rev. 2014 Jul-Sep;16(3):144-51. Review.

PMID:
25102336
15.

Sodium glucose co-transporter 2 (SGLT2) inhibitors: new among antidiabetic drugs.

Opie LH.

Cardiovasc Drugs Ther. 2014 Aug;28(4):331-4. doi: 10.1007/s10557-014-6522-0. Review.

PMID:
24825435
16.

Lowering plasma glucose concentration by inhibiting renal sodium-glucose cotransport.

Abdul-Ghani MA, DeFronzo RA.

J Intern Med. 2014 Oct;276(4):352-63. doi: 10.1111/joim.12244. Review.

17.

Inhibition of renal glucose reabsorption as a novel treatment for diabetes patients.

Cersosimo E, Solis-Herrera C, Triplitt C.

J Bras Nefrol. 2014 Jan-Mar;36(1):80-92. Review.

18.

Ifosfamide-induced Fanconi syndrome with diabetes insipidus.

Leem AY, Kim HS, Yoo BW, Kang BD, Kim MH, Rha SY, Kim HS.

Korean J Intern Med. 2014 Mar;29(2):246-9. doi: 10.3904/kjim.2014.29.2.246. Review.

19.

Unusual manifestation of crystalline light chain tubulopathy in patient with multiple myeloma: case report and review of the literature.

Stompór T, Perkowska-Ptasińska A, Wojciechowska M, Zając K, Chmielewska-Badziąg A, Pawłowska A.

Ren Fail. 2014 Jun;36(5):795-9. doi: 10.3109/0886022X.2014.884446. Review.

PMID:
24512271
20.

SGLT2-inhibitors: a novel class for the treatment of type 2 diabetes introduction of SGLT2-inhibitors in clinical practice.

Cuypers J, Mathieu C, Benhalima K.

Acta Clin Belg. 2013 Jul-Aug;68(4):287-93. Review.

PMID:
24455799
Items per page

Supplemental Content

Loading ...
Support Center